Tags

Type your tag names separated by a space and hit enter

Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.
Diabetes Metab J. 2015 Feb; 39(1):74-81.DM

Abstract

BACKGROUND

To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice.

METHODS

An observational, retrospective study was performed. Patients aged ≥30 years treated with metformin who initiated a second oral antidiabetic treatment in 2009 to 2010 were included. Two groups of patients were analysed: metformin+DPP-4 inhibitors and other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated hemoglobin< 7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for 2 years.

RESULTS

We included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin+DPP-4 inhibitors and 260 patients received metformin+other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%), and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (P<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), P=0.001.

CONCLUSION

Despite the limitations of the study, patients with renal impairment treated with DPP-4 inhibitors had better metabolic control, lower rates (association) of hypoglycaemia, and lower health costs for the Spanish national health system.

Authors+Show Affiliations

Management Planning, Badalona Serveis Assistencials SA, Barcelona, Spain.Medical Documentation, Hospital Germans Trias i Pujol, Barcelona, Spain.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25729716

Citation

Sicras-Mainar, Antoni, and Ruth Navarro-Artieda. "Economic Impact of Combining Metformin With Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Renal Impairment in Spanish Patients." Diabetes & Metabolism Journal, vol. 39, no. 1, 2015, pp. 74-81.
Sicras-Mainar A, Navarro-Artieda R. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients. Diabetes Metab J. 2015;39(1):74-81.
Sicras-Mainar, A., & Navarro-Artieda, R. (2015). Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients. Diabetes & Metabolism Journal, 39(1), 74-81. https://doi.org/10.4093/dmj.2015.39.1.74
Sicras-Mainar A, Navarro-Artieda R. Economic Impact of Combining Metformin With Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Renal Impairment in Spanish Patients. Diabetes Metab J. 2015;39(1):74-81. PubMed PMID: 25729716.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients. AU - Sicras-Mainar,Antoni, AU - Navarro-Artieda,Ruth, Y1 - 2015/02/16/ PY - 2014/06/18/received PY - 2014/08/19/accepted PY - 2015/3/3/entrez PY - 2015/3/3/pubmed PY - 2015/3/3/medline KW - Cardiovascular events KW - Diabetes KW - Dipeptidyl-peptidase 4 inhibitors KW - Health care costs KW - Metabolic control KW - Renal impairment SP - 74 EP - 81 JF - Diabetes & metabolism journal JO - Diabetes Metab J VL - 39 IS - 1 N2 - BACKGROUND: To evaluate resource use and health costs due to the combination of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with diabetes and renal impairment in routine clinical practice. METHODS: An observational, retrospective study was performed. Patients aged ≥30 years treated with metformin who initiated a second oral antidiabetic treatment in 2009 to 2010 were included. Two groups of patients were analysed: metformin+DPP-4 inhibitors and other oral antidiabetics. The main measures were: compliance, persistence, metabolic control (glycosylated hemoglobin< 7%) and complications (hypoglycemia, cardiovascular events) and total costs. Patients were followed up for 2 years. RESULTS: We included 395 patients, mean age 70.2 years, 56.5% male: 135 patients received metformin+DPP-4 inhibitors and 260 patients received metformin+other oral antidiabetics. Patients receiving DPP-4 inhibitors showed better compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%), and metabolic control (63.9% vs. 57.3%), respectively, compared with those receiving other oral antidiabetics (P<0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower total costs (€ 2,486 vs. € 3,002), P=0.001. CONCLUSION: Despite the limitations of the study, patients with renal impairment treated with DPP-4 inhibitors had better metabolic control, lower rates (association) of hypoglycaemia, and lower health costs for the Spanish national health system. SN - 2233-6079 UR - https://www.unboundmedicine.com/medline/citation/25729716/Economic_impact_of_combining_metformin_with_dipeptidyl_peptidase_4_inhibitors_in_diabetic_patients_with_renal_impairment_in_spanish_patients_ L2 - https://e-dmj.org/DOIx.php?id=10.4093/dmj.2015.39.1.74 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.